The average gap between NHI prices and the market prices of listed medicines in Japan stood at a preliminary 5.2%…
HOME > BUSINESS
BUSINESS
- PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu
May 16, 2013
- Investigation on Ranbaxy Quality Issue Ends, Risks Eliminated: Daiichi Sankyo Pres.
May 15, 2013
- Eisai Forecasts 1st Sales Rise in 4 Years in FY2013, Business Slump to Bottom Out: Pres. Naito
May 15, 2013
- Otsuka Holdings’ Pharma Sales Up 8.8% in FY2012, Spurred by Upbeat Abilify
May 15, 2013
- Diabetes Treatment Market to Exceed 500 Billion Yen in 2017: Fuji-Keizai
May 15, 2013
- Eight Companies Initiate Voluntary Recall of Enalapril Generics Due to Deviations from Specifications
May 15, 2013
- Astellas’s FY2012 Sales Top 1 Trillion Yen; XTANDI Scores 12.2 Billion Yen in 1st Year
May 14, 2013
- Ono Sales Down 0.3% Despite New Product Sales Increase, Double-Digit Decline in Profits Due to Higher Cost to Sales Ratio
May 14, 2013
- Takeda Not to Release 3-Year Mid-Term Business Plan, Changes to Annual Business Forecast
May 14, 2013
- Eisai Operating Profit Down 26%, Fails to Meet Revised Domestic Sales Target for Aricpet
May 14, 2013
- Daiichi Sankyo FY2012 Sales Up 6.3%; Leads Way with Near Double-Digit Growth in Japan Pharma Biz
May 14, 2013
- Four Leading Wholesalers See Clear Recovery in Pharmaceutical Wholesale Business
May 14, 2013
- DSP to Increase Latuda Sales Force to 450 in North America
May 13, 2013
- Yakult Pharmaceutical Sales and Profit Down as Elplat Sales Decline
May 13, 2013
- Millennium: Anna Protopapas Becomes President, R&D Functions Integrated into Takeda
May 13, 2013
- Ethical Drug Sales Down 0.7%, OTC Drug Sales Surge 8.9% in March: Crecon Report
May 13, 2013
- Meiji Seika Pharma Leads in Percentage of Female MRs with a Ratio of 1 Female to 3 MRs: Jiho Survey
May 13, 2013
- MTPC Royalties Reach 19.5 Billion Yen from Out-Licensed Gilenya
May 10, 2013
- Shionogi Chalks Up Record Profits as US Unit Buoys Sales
May 10, 2013
- DSP Sales Down 0.8% Due to Long-Listed Product Sales Decline, Double-Digit Growth in Profits
May 10, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…